HC Wainwright & Co. maintains Biodesix at Buy, lowers price target to $34 from $38
HC Wainwright & Co. kept Biodesix's rating at Buy but reduced its price target to $34 from $38, a 10.5% cut. This implies a 298.6% upside from the Nov 6 close of $8.53.
How this was made

The 30-second read
Why it matters
The downgrade signals a short‑term bearish bias, but the stock's low float could lead to volatility.
Market read
Analyst target reduction is the primary new information, offering a modest trading cue for BDSX.
What to watch
Potential upcoming FDA interactions or partnership announcements not covered in the brief.
Background
Biodesix is a diagnostic company focused on lung disease testing. Analyst coverage is limited, making target changes notable for traders.
Ticker impact
HC Wainwright lowered Biodesix's price target to $34 from $38, indicating a bearish analyst view.
likely pressure as the market prices in the lower target
Target reductions often precede short‑term price declines, especially for micro‑caps.
Market effects
Minimal; reflects broader analyst caution on diagnostic biotech stocks.
Limited to US biotech sector.
Low; no global macro implications.
Counterpoint
Target cut may be overly pessimistic if upcoming trial data exceeds expectations.
Key entities
- Analyst FirmHC Wainwright & Co.
Equity research firm that issued the rating and target change.
- CompanyBiodesix Inc.
US‑listed diagnostic biotech (ticker BDSX).


